XOMA (NASDAQ:XOMA) Downgraded to Hold at StockNews.com

XOMA (NASDAQ:XOMAGet Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Several other research analysts also recently commented on XOMA. TheStreet raised shares of XOMA from a “c-” rating to a “b-” rating in a report on Friday, April 1st. Zacks Investment Research lowered shares of XOMA from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, XOMA currently has a consensus rating of “Hold” and a consensus target price of $49.00.

Shares of XOMA stock traded down $0.33 during mid-day trading on Friday, reaching $23.46. 21,271 shares of the company’s stock traded hands, compared to its average volume of 27,679. XOMA has a 12 month low of $19.08 and a 12 month high of $39.49. The firm has a 50 day moving average price of $24.85 and a two-hundred day moving average price of $23.42. The firm has a market capitalization of $267.35 million, a PE ratio of 156.41 and a beta of 0.89.

XOMA (NASDAQ:XOMAGet Rating) last issued its earnings results on Tuesday, March 8th. The biotechnology company reported $1.67 earnings per share for the quarter, missing the consensus estimate of $2.27 by ($0.60). The firm had revenue of $35.94 million during the quarter, compared to the consensus estimate of $34.84 million. XOMA had a return on equity of 4.93% and a net margin of 14.57%.

In other news, CEO James R. Neal sold 50,000 shares of the stock in a transaction that occurred on Monday, March 21st. The shares were sold at an average price of $29.00, for a total transaction of $1,450,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Thomas M. Burns sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, March 22nd. The shares were sold at an average price of $30.02, for a total transaction of $70,216.78. The disclosure for this sale can be found here. Insiders sold a total of 53,450 shares of company stock worth $1,553,569 over the last 90 days. Insiders own 9.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Geneos Wealth Management Inc. acquired a new stake in XOMA in the third quarter valued at approximately $25,000. Citigroup Inc. boosted its stake in XOMA by 118.0% in the fourth quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in XOMA by 138.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 834 shares in the last quarter. Barclays PLC raised its holdings in shares of XOMA by 222.0% in the third quarter. Barclays PLC now owns 2,463 shares of the biotechnology company’s stock worth $61,000 after buying an additional 1,698 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of XOMA by 181.6% in the second quarter. Morgan Stanley now owns 2,630 shares of the biotechnology company’s stock worth $90,000 after buying an additional 1,696 shares during the last quarter. Institutional investors own 56.14% of the company’s stock.

XOMA Company Profile (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Featured Stories

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.